Servier

PARIS, September 5, 2011 - - Positive Correlation Established Between Valdoxan's Efficacy and Disease Severity New data, presented today at the 24th European College of Neuropsychopharmacology (ECNP) Congress, further highlight the distinctive profile of efficacy of Valdoxan (agomelatine) in the treatment of anxiety in depressed patients when compared with other commonly prescribed antidepressants.

PARIS, August 29, 2011 - Results from CLARIFY, the largest international registry ever carried out in stable coronary artery disease (CAD) outpatients, show that despite the widespread use of β-blockers, one third of CAD patients had a resting heart rate (HR) of 70bpm,[1] a rate that has previously been shown to be linked with higher prevalence and severity of angina and heart attacks.[2] The CLARIFY results, representing more than 30000 patients from 45 countries worldwide, are presented today at the European Society of Cardiology congress.

PARIS, August 29, 2011 - - For The First Time: Direct Link Found Between Reducing Heart Rate and Quality of Life New results from SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), the largest-ever morbi-mortality study of treatments for chronic heart failure, reveal for the first time a direct link between heart rate reduction and quality of life in patients with heart failure.[1] The new data from the SHIFT study with Procoralan (ivabradine), presented today at the European Society of Cardiology congress, are clinically important as quality of life is greatly impaired in patients with chronic heart failure and poor quality of life in these patients is associated with worse disease outcomes.

VALENCIA, Spain, March 24, 2011 - Protelos(R) (strontium ranelate) has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis (ECCEO011-IOF) in Valencia.[i] Through its unique dual impact on both bone formation and resorption, Protelos substantially reduces fracture risk, the primary goal of osteoporosis treatment.

AMSTERDAM, August 31, 2010 - Valdoxan(R)/Thymanax(R) (agomelatine) is more efficacious than both conventional selective serotonin reuptake inhibitor (SSRI) and serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants, according to new data presented today at the 23rd European College of Neuropsychopharmacology (ECNP) Congress.